ATOVAQUONE Drug Patent Profile
✉ Email this page to a colleague
When do Atovaquone patents expire, and what generic alternatives are available?
Atovaquone is a drug marketed by Abhai Llc, Abon Pharms Llc, Amneal Pharms, Apotex, Bionpharma, Chartwell Rx, Glenmark Pharms, Hetero Labs Ltd Iii, Lupin Ltd, Glenmark Pharms Ltd, and Mylan. and is included in eleven NDAs.
The generic ingredient in ATOVAQUONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone
A generic version of ATOVAQUONE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATOVAQUONE?
- What are the global sales for ATOVAQUONE?
- What is Average Wholesale Price for ATOVAQUONE?
Summary for ATOVAQUONE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 18 |
Raw Ingredient (Bulk) Api Vendors: | 166 |
Clinical Trials: | 42 |
Patent Applications: | 5,089 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ATOVAQUONE |
DailyMed Link: | ATOVAQUONE at DailyMed |
![ATOVAQUONE drug patent expirations Drug patent expirations by year for ATOVAQUONE](/p/graph/s/t/ATOVAQUONE-patent-expirations.png)
![Drug Prices for ATOVAQUONE](/p/graph/drug-price/ATOVAQUONE.png)
Recent Clinical Trials for ATOVAQUONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Naval Medical Research Unit TWO (NAMRU-2) | Phase 4 |
Naval Medical Research Center | Phase 4 |
Naval Environmental Preventive Medicine Unit TWO (NEPMU-2) | Phase 4 |
Pharmacology for ATOVAQUONE
Drug Class | Antimalarial Antiprotozoal |
Medical Subject Heading (MeSH) Categories for ATOVAQUONE
Anatomical Therapeutic Chemical (ATC) Classes for ATOVAQUONE
Paragraph IV (Patent) Challenges for ATOVAQUONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MEPRON | Oral Suspension | atovaquone | 750 mg/5 mL | 020500 | 1 | 2009-10-20 |
US Patents and Regulatory Information for ATOVAQUONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abhai Llc | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 210510-001 | May 31, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Glenmark Pharms | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 209685-001 | Nov 21, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Apotex | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 209750-001 | Oct 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Mylan | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | atovaquone; proguanil hydrochloride | TABLET;ORAL | 202362-001 | May 27, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hetero Labs Ltd Iii | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 210692-001 | Oct 11, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Abon Pharms Llc | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 214272-001 | Oct 25, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |